electroCore, Inc.
NASDAQ:ECOR

Watchlist Manager
electroCore, Inc. Logo
electroCore, Inc.
NASDAQ:ECOR
Watchlist
Price: 16.26 USD -7.19% Market Closed
Market Cap: 106.5m USD
Have any thoughts about
electroCore, Inc.?
Write Note

electroCore, Inc.
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

electroCore, Inc.
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
electroCore, Inc.
NASDAQ:ECOR
Gross Profit
$19.4m
CAGR 3-Years
87%
CAGR 5-Years
77%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Gross Profit
$9.2B
CAGR 3-Years
2%
CAGR 5-Years
2%
CAGR 10-Years
8%
Boston Scientific Corp
NYSE:BSX
Gross Profit
$11B
CAGR 3-Years
13%
CAGR 5-Years
8%
CAGR 10-Years
8%
Stryker Corp
NYSE:SYK
Gross Profit
$14B
CAGR 3-Years
9%
CAGR 5-Years
8%
CAGR 10-Years
8%
Abbott Laboratories
NYSE:ABT
Gross Profit
$23B
CAGR 3-Years
-2%
CAGR 5-Years
5%
CAGR 10-Years
8%
Intuitive Surgical Inc
NASDAQ:ISRG
Gross Profit
$5.3B
CAGR 3-Years
12%
CAGR 5-Years
12%
CAGR 10-Years
14%
No Stocks Found

electroCore, Inc.
Glance View

Market Cap
105.8m USD
Industry
Health Care

electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. The company is headquartered in Rockaway, New Jersey and currently employs 52 full-time employees. The company went IPO on 2018-06-22. nVNS is a platform for bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The firm is providing gammaCore device for the treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults. gammaCore permits patients to self-administer doses of nVNS on an as-needed basis for treatment of prevent multiple types of headache pain via the vagus nerve. The gammaCore therapy is also used to treat primary headache, including migraine, cluster headache (CH), hemicrania continua and paroxysmal hemicrania (PH) and coronavirus (COVID-19).

ECOR Intrinsic Value
18.49 USD
Undervaluation 12%
Intrinsic Value
Price

See Also

What is electroCore, Inc.'s Gross Profit?
Gross Profit
19.4m USD

Based on the financial report for Sep 30, 2024, electroCore, Inc.'s Gross Profit amounts to 19.4m USD.

What is electroCore, Inc.'s Gross Profit growth rate?
Gross Profit CAGR 5Y
77%

Over the last year, the Gross Profit growth was 76%. The average annual Gross Profit growth rates for electroCore, Inc. have been 87% over the past three years , 77% over the past five years .

Back to Top